ReviewSeminars in thrombosis and hemostasis2010
Targeting antioxidant and antithrombotic biotherapeutics to endothelium.
Review in Seminars in thrombosis and hemostasis, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 27 citations in OpenAlex.
- Sustained Inhibition of NF-κB Activity Mitigates Retinal Vasculopathy in Diabetes.The American journal of pathology · 2021Article
- Targeting therapeutics to endothelium: are we there yet?Drug delivery and translational research · 2018Review
- Dual targeting of therapeutics to endothelial cells: collaborative enhancement of delivery and effect.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2015Article
- Endothelial targeting of nanocarriers loaded with antioxidant enzymes for protection against vascular oxidative stress and inflammation.Biomaterials · 2014Article
- Article
- Article
- Nanocarriers for vascular delivery of antioxidants.Nanomedicine (London, England) · 2011Review
- Vascular targeting of antithrombotic agents.IUBMB life · 2011Review
- Targeted modulation of reactive oxygen species in the vascular endothelium.Journal of controlled release : official journal of the Controlled Release Society · 2011Article
- Targeted Nanocarriers for Imaging and Therapy of Vascular Inflammation.Current opinion in colloid & interface science · 2011Article
- Liposomal Antioxidants for Protection against Oxidant-Induced Damage.Journal of toxicology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
The endothelium is one of the key targets for pharmacological interventions in oxidative stress and thrombosis, two conditions that are notoriously difficult to treat due to limited efficacy and precision of action of current drugs. Design of molecular and nano-devices that deliver potent antioxidant and antithrombotic therapeutic enzymes to the endothelium holds promise to improve the potency, localization, timing, specificity, safety, and mechanistic precision of these interventions. In particular, cell adhesion molecules expressed on the surface of resting and pathologically altered endothelial cells can be used for drug delivery to the endothelial surface (preferable for thrombolytics) and into intracellular compartments (preferable for antioxidants). Drug delivery platforms including protein conjugates, recombinant fusion constructs, and stealth polymer carriers designed to target these drugs to endothelium are reviewed in this article.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.